What changes in this sector
- Regulation
- Medical devices fall under the Medical Devices Ordinance (MedDO), aligned with the European MDR and supervised by Swissmedic. Since 26 May 2021, the mutual recognition agreement with the EU no longer covers devices: to sell in the EU you need a European authorised representative, and a foreign manufacturer must appoint a representative in Switzerland. Swissmedic
- Clinical trials
- A clinical trial needs approval from the competent ethics committee, filed through the BASEC portal, and depending on the risk category from Swissmedic. The trial only starts once both are granted. Build this delay into your fundraising plan. Swissmedic, clinical trials of medical devices
- Reimbursement
- Getting into the tariffs of mandatory health insurance is often the real commercial milestone. Investors will ask for your path to reimbursement, on top of your regulatory path.
- Funding path
- Often non-dilutive first: an Innosuisse innovation project with a research partner, BRIDGE, Venture Kick. Then sector business angels and health funds, with rounds that take longer to close. Innosuisse
- What investors look at
- The device's risk class, the clinical evidence, the regulatory timeline and a quality system in place (ISO 13485).
- Where it happens
- Biopôle in Lausanne, Campus Biotech in Geneva, Basel and Zurich.
Checked on 5 November 2026. An error or a rule change? Write to us.
Who keeps coming back in rounds
- FIT Vaud (Innovaud) 14 rounds
- FIF Genève 5 rounds
- Biopôle SA 4 rounds
- N&V Capital 3 rounds
- Venture Kick 3 rounds
- Zürcher Kantonalbank 3 rounds
Recent rounds
November 2026
- CHF 1.3 M
- Amount not disclosed
- CARECHF 2.3 M
CARE runs a health prevention platform used by more than 10,000 people.
- UNDAE ScienceCHF 1.2 M
UNDAE Science is developing Noctae, an at-home sleep analysis platform based on a sensor mat placed on the mattress.
- avaisorCHF 488,000
avaisor captures and transmits surgeons' reasoning, going beyond simple surgical video.
October 2026
- TrilliomeCHF 10,000
Trilliome develops patented ingredients that act on the gut-brain axis for metabolic and cognitive health.
- PolaSightCHF 100,000
PolaSight, a University of Bern spin-off, maps a fresh tissue sample in one minute during cancer surgery.
- JIVITAAmount not disclosed
JIVITA integrates complementary medicine care into the inpatient operations of partner clinics, including two Hirslanden clinics in Zurich.
- CHD (Connected Health Development)CHF 150,000
CHD, a medtech based on the Biopôle campus, is developing a connected textile belt to remotely monitor high-risk pregnancies.
- DistalmotionAmount not disclosed
Distalmotion is developing DEXTER, a robotic surgery system designed for ambulatory surgery centres.
- dEEGtalCHF 100,000
dEEGtal, based at the Wyss Center on the Campus Biotech, uses AI to analyse electroencephalograms and refine epilepsy diagnosis.
- AVEAAmount not disclosed
AVEA develops science-based food supplements and longevity products, and generated CHF 21 million in revenue in 2025.
Active investors in the sector
- 3VC VC · Stage not specified across recorded rounds · Ticket sizes not disclosed; one recorded round of USD 10 M (Ahead Health)
- 4FO Ventures Family office · A–B · 2–15M
- ACE Ventures VC · Seed and stage not specified across recorded rounds · Ticket sizes not disclosed; recorded rounds of USD 3 M to USD 5.4 M
- Biopôle SA Grant · Non-dilutive funding for start-ups on the Biopôle campus · Up to CHF 90 000 per start-up, plus a CHF 250 000 Pre-Clinical Top-Up
- Business Angels Léman Business angels · Pre-seed–Seed · CHF 25–250K
- Concentric VC · Seed and stage not specified across recorded rounds · Ticket sizes not disclosed
- Conda Crowdfunding · Crowdinvesting campaigns and convertible loan across recorded rounds · Ticket sizes not disclosed; amounts raised of CHF 173 000 to CHF 2.3 M
- DART Ventures VC · Pre-seed–Seed · 0.25–1.5M
- DayOne Accelerator · Seed · CHF 100K
- Earlybird VC · Pre-seed to Series A across recorded rounds · Ticket sizes not disclosed; recorded rounds of EUR 2.7 M to USD 15 M
- Eurostars Grant · Non-dilutive R&D grants to consortia across recorded rounds · Eurostars funding of EUR 1 to 1.3 M per consortium (including EUR 772 000 for Terapet)
- Evercurious VC VC · Seed across recorded rounds · Ticket sizes not disclosed; recorded rounds of CHF 1.8 M to USD 4.5 M
- Forestay Capital Family office · Seed–A · 1–10M
- GoHub Ventures VC · Seed across recorded rounds · Ticket sizes not disclosed
- Kickfund VC · Pre-seed to Series A across recorded rounds · Ticket sizes not disclosed; recorded rounds of CHF 1.5 M to EUR 13.4 M
- Lichtsteiner Foundation Grant · Seed across recorded rounds · Tickets not disclosed; recorded rounds of CHF 1.25 M to USD 5.1 M
- Marc Maurer Business angels · Series A across recorded rounds · Tickets not disclosed
- N&V Capital VC · Seed to growth across recorded rounds · Tickets not disclosed; recorded rounds of USD 3.3 M to USD 25 M
- Perceptive Advisors VC · Series B and debt financing across recorded rounds · Loan of up to USD 70 M (Distalmotion); equity tickets not disclosed
- Protocol Labs VC · Seed and round not specified across recorded rounds · Tickets not disclosed; recorded rounds of USD 7.5 M to USD 15 M
- QAI Ventures VC · Pre-seed and seed across recorded rounds · Tickets not disclosed; recorded rounds of CHF 2 M to USD 3.3 M
- Redstone VC VC · Pre-seed and seed across recorded rounds · Tickets not disclosed; recorded rounds of USD 2 M to CHF 4.6 M
- RTP Global VC · Pre-seed to seed, then follow-on round across recorded rounds · Tickets not disclosed; recorded rounds of USD 1.5 M to USD 10 M
- Speedinvest VC · Seed to Series A across recorded rounds · Tickets not disclosed; recorded rounds of USD 15 M to USD 16 M
- Thomas Wolf Business angels · Seed to Series A across recorded rounds · Tickets not disclosed
- VI Partners VC · Seed–A · 0.5–5M